Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Paul Greengard Patents
Inventor:
Greengard; Paul
Address:
New York, NY
No. of patents:
16
Patents:












Patent Number Title Of Patent Date Issued
7910586 Compositions and methods for prevention and treatment of amyloid-.beta. peptide-related disorder March 22, 2011
The present invention provides methods and compositions for modulating levels of amyloid-.beta. peptide (A.beta.) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate A.beta. levels. The invention also
7427485 Method for classification of anti-psychotic drugs September 23, 2008
The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-
7320785 Compositions and methods for modulation of DARPP-32 phosphorylation January 22, 2008
The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin-
7129073 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways October 31, 2006
The present invention provides methods and compositions for modulating the activities of metabotropic glutamate receptor intracellular signaling molecules. The present invention provides methods and compositions for modulating the activities of casein kinase I and/or cyclin-dependent
6989362 Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphor January 24, 2006
The present invention discloses that DARPP-32 is substrate for the cyclin dependent kinase Cdk5. The phosphorylation takes place at a specific threonine residue of DARPP-32 (Threonine 75). The Cdk5 catalyzed phosphorylation of DARPP-32 converts this protein into an inhibitor of the c
6444201 Treatment of alzheimer disease by modulation of synapsins September 3, 2002
The role of synapsin II in both the reformation and the maintenance of synaptic connections in cultured hippocampal neurons can be the basis of therapy for neurodegenerative disorder, particularly Alzheimer disease, which involve the disruption of synapses. When synapsin II expression in
6429010 DNA encoding the human synapsin III gene and uses thereof August 6, 2002
A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. Furthermore, isoforms of synapsin III, e.g., synapsin IIIa, IIIb and IIIc, and have isolated and characterized, and cDNA encoding these isoforms has also bee
6040168 DNA encoding the human synapsin III gene and uses thereof March 21, 2000
A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The
6013621 Method of treating psychosis and/or hyperactivity January 11, 2000
The present invention discloses the bidirectional regulation of DARPP-32 phosphorylation by dopamine and dopamine D1 and D2 receptors. This disclosure leads to new methodology in the treatment of schizophrenia and related disorders. In addition, the present invention provides methods for
5928882 Treatment and prevention of neurodegenerative diseases using modulators of Fe65 July 27, 1999
Modulators of the protein Fe65 can be utilized to affect the interaction of the protein Fe65 with the cytoplasmic domain of amyloid precursor protein and thus provide therapeutics for the treatment and/or prevention of neurodegenerative diseases, such as Alzheimer's disease and dementia.
5777195 Knockout mutant mouse for DARPP-32 and use thereof July 7, 1998
A knockout mouse containing a non-functional allele for the gene that naturally encodes and expresses functional DARPP-32 is disclosed. This mouse contains two non-functional alleles for the gene that naturally encodes and expresses functional DARPP-32, and therefore is unable to exp
5538983 Method of treating amyloidosis by modulation of calcium July 23, 1996
Various first messengers linked to phospholipase C, including acetylcholine and interleukin-1, regulate the production both of the secreted form of the amyloid protein precursor and of amyloid .beta.-protein. Intracellular signals which are responsible for mediating these effects have no
5385915 Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphory January 31, 1995
A method of regulating phosphorylation of proteins involved in controlling processing or function of key proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques associated with Alzheimer disease comprising introducing an effective amount of a kinase
5348963 Method of screening for modulators of amyloid formation September 20, 1994
Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and
5242932 Treatment of amyloidosis associated with Alzheimer disease September 7, 1993
Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and
4874694 Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders October 17, 1989
A diagnostic method for neurological and psychiatric disorders utilizes the cerebrospinal fluid incubated in the presence of 32-P labelled ATP and an appropriate protein kinase. After termination of the reaction, a sample is applied to gels for electrophoresis. Subsequent autoradiography










 
 
  Recently Added Patents
Implant for performance enhancement of selected transistors in an integrated circuit
Bioactive agent-loaded heart-targeting nanoparticles
Method for growing group III-nitride crystals in supercritical ammonia using an autoclave
Wristwatch
Three-term predictive adder and/or subtracter
Reovirus for the treatment of cellular proliferative disorders
Method for dynamic multi-level pricing for wireless communications according to quality of service
  Randomly Featured Patents
Light shield sheet, optical apparatus, and method of manufacturing light shield sheet
System and method for automatically adjusting game controller sensitivity to player inputs
Transmissively read optical recording medium
Method of controlling and optimizing industrial processes for the manufacture of textile finishing and improving agents via flow injection analysis
Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
Electrostatic duplicator for multicolor imagery
Process for recovering refractile bodies containing heterologous proteins from microbial hosts
Cloning and/or expression vectors, preparation method and their use
Microcentrifuge tube cap opening and closing apparatus and method
Antenna device